Literature DB >> 10395652

Signaling events induced by lipopolysaccharide-activated toll-like receptor 2.

R B Yang1, M R Mark, A L Gurney, P J Godowski.   

Abstract

Human Toll-like receptor 2 (TLR2) is a signaling receptor that responds to LPS and activates NF-kappaB. Here, we investigate further the events triggered by TLR2 in response to LPS. We show that TLR2 associates with the high-affinity LPS binding protein membrane CD14 to serve as an LPS receptor complex, and that LPS treatment enhances the oligomerization of TLR2. Concomitant with receptor oligomerization, the IL-1R-associated kinase (IRAK) is recruited to the TLR2 complex. Intracellular deletion variants of TLR2 lacking C-terminal 13 or 141 aa fail to recruit IRAK, which is consistent with the inability of these mutants to transmit LPS cellular signaling. Moreover, both deletion mutants could still form complexes with wild-type TLR2 and act in a dominant-negative (DN) fashion to block TLR2-mediated signal transduction. DN constructs of myeloid differentiation protein, IRAK, TNF receptor-associated factor 6, and NF-kappaB-inducing kinase, when coexpressed with TLR2, abrogate TLR2-mediated NF-kappaB activation. These results reveal a conserved signaling pathway for TLR2 and IL-1Rs and suggest a molecular mechanism for the inhibition of TLR2 by DN variants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity.

Authors:  G Zhang; S Ghosh
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts.

Authors:  K Tabeta; K Yamazaki; S Akashi; K Miyake; H Kumada; T Umemoto; H Yoshie
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 3.  Molecular events of bacterial-induced maturation of dendritic cells.

Authors:  M Rescigno; F Granucci; P Ricciardi-Castagnoli
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 4.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

Review 5.  Toll-like receptors: molecular mechanisms of the mammalian immune response.

Authors:  H D Brightbill; R L Modlin
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

6.  Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs.

Authors:  Graciela Andonegui; Claudine S Bonder; Francis Green; Sarah C Mullaly; Lori Zbytnuik; Eko Raharjo; Paul Kubes
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

7.  TRAF6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasma gondii.

Authors:  Nicola J Mason; Jim Fiore; Takashi Kobayashi; Katherine S Masek; Yongwon Choi; Christopher A Hunter
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 8.  Accessory molecules for Toll-like receptors and their function.

Authors:  Clarissa C Lee; Ana M Avalos; Hidde L Ploegh
Journal:  Nat Rev Immunol       Date:  2012-02-03       Impact factor: 53.106

9.  Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients.

Authors:  Gundi Heuschen; Christine Leowardi; Ulf Hinz; Frank Autschbach; Andreas Stallmach; Christian Herfarth; Udo A Heuschen
Journal:  Int J Colorectal Dis       Date:  2006-06-13       Impact factor: 2.571

10.  Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion.

Authors:  Young Chan Lee; Chul Kim; Ju Sup Shim; Jae Yong Byun; Mun Suh Park; Chang Il Cha; Young Il Kim; Jin Woo Lee; Seung Geun Yeo
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-12-26       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.